RUNX1 and breast cancer: Further research is needed to determine how IGF2BP1 and RUNX1-IT1 interact with each other and their specific binding regions, so as to design some oligonucleotides or peptides to block their binding, which may be a novel therapeutic strategy for breast cancer.